An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.

Robert BissonnetteAndreas PinterLaura K FerrisSascha GerdesPhoebe RichRonald VenderMegan MillerYaung-Kaung ShenArun KannanShu LiCynthia DeKlotzKim A Papp

Published in: The New England journal of medicine (2024)

After 16 weeks of once- or twice-daily oral administration, treatment with the interleukin-23-receptor antagonist peptide JNJ-77242113 showed greater efficacy than placebo in patients with moderate-to-severe plaque psoriasis. (Funded by Janssen Research and Development; FRONTIER 1 ClinicalTrials.gov number, NCT05223868.).

Keyphrases

coronary artery disease
physical activity
early onset
combination therapy
drug induced
replacement therapy
hidradenitis suppurativa